Advertisement

123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging

  • Nicole Moins
  • Michel D'Incan
  • Jacques Bonafous
  • Franck Bacin
  • Pierre Labarre
  • Marie-France Moreau
  • Danièle Mestas
  • Elisabeth Noirault
  • Florence Chossat
  • Eric Berthommier
  • Janine Papon
  • Martine Bayle
  • Pierre Souteyrand
  • Jean-Claude Madelmont
  • Annie Veyre
Original Article

Abstract.

Melanoma is a neoplasia of dramatically increasing incidence that has a propensity to spread rapidly. Early detection is fundamental and patient management requires reliable, sensitive and reproducible staging methods, such as a single examination by planar scintigraphy or single-photon emission tomography (SPET) using a radiopharmaceutical with selectivity for melanoma tissue. Among iodobenzamides reported to possess an affinity for melanoma, a new compound, N-(2-diethylaminoethyl)-2-iodobenzamide (BZA2), was selected for a clinical trial in view of its pharmacokinetic experimental profile in melanoma-bearing mice. Planar whole-body scintigraphy using 123I-BZA2 was performed in 25 patients with histologically proven cutaneous melanoma. Performance was evaluated in two groups of patients with one or more documented secondary lesions (n=13) or with no known secondary lesions (n=12), and results were compared with those of conventional investigation techniques. No adverse clinical or biological events were recorded. Lesions were imaged by increased tracer uptake, and good quality images were obtained 4 h after administration. After a follow-up of more than 1 year, the overall results of 123I-BZA2 scintigraphy on a per patient basis showed a sensitivity of 100%, a specificity of 95%, a positive predictive value of 86% and a negative predictive value of 100%. The proven secondary lesions were imaged with a sensitivity of 100% and a specificity of 91%. In seven patients with suspected metastases, the absence of 123I-BZA2 uptake was confirmed as true negative, and in one patient without suspected metastases, 123I-BZA2 scintigraphy revealed a gastric lesion. Hence eight diagnoses would have been modified by 123I-BZA2 scintigraphy data. 123I-BZA2 allowed discrimination between benign and malignant lesions and, in the case of malignancies, between those of melanomatous origin and others. This compound, which is selective for melanoma tissue, appears promising for the staging and restaging of melanoma.

Melanoma Radiopharmaceuticals Iodobenzamides SPET imaging 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Nicole Moins
    • 1
  • Michel D'Incan
    • 2
  • Jacques Bonafous
    • 1
  • Franck Bacin
    • 4
  • Pierre Labarre
    • 1
  • Marie-France Moreau
    • 1
  • Danièle Mestas
    • 3
  • Elisabeth Noirault
    • 1
  • Florence Chossat
    • 5
  • Eric Berthommier
    • 5
  • Janine Papon
    • 1
  • Martine Bayle
    • 1
  • Pierre Souteyrand
    • 2
  • Jean-Claude Madelmont
    • 1
  • Annie Veyre
    • 1
  1. 1.UMR 484 INSERM-Université d'Auvergne, Centre Jean Perrin, Rue Montalembert, BP 184, 63005 Clermont-Ferrand, France
  2. 2.Department of Dermatology, CHU, Clermont-Ferrand, France
  3. 3.Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France
  4. 4.Department of Ophtalmology, CHU, Clermont-Ferrand, France
  5. 5.CIS bio international, Gif-sur-yvette, France

Personalised recommendations